Diet Induced Ketosis for Brain Injury - A Feasibility Study
Primary Purpose
Brain Injuries, Traumatic Brain Injury, Subarachnoid Hemorrhage
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Ketogenic diet with added MCT
Sponsored by
About this trial
This is an interventional treatment trial for Brain Injuries
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with severe acquired brain injury (TBI, stroke, SAH, anoxic brain injury or neuroinfection)
- Patients ≥ 18 years
- Understand and speak Scandinavian language
- Informed consent from patient or deputy consent if the patient is unable to give consent due to reduced state of consciousness
- Expectation of prolonged hospitalization
Exclusion Criteria:
- Contraindication to a ketogenic diet
- Dysregulated Diabetes Mellitus
- Medicated for elevated triglycerides
Sites / Locations
- Clinic of Neurorehabilitation / TBI Unit, Rigshospitalet (Satellite Department on Hvidovre Hospital)
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Ketogenic diet with MCT
Arm Description
Ketogenic Diet supplemented with MCT everyday for 6 weeks.
Outcomes
Primary Outcome Measures
Can the intervention be completed during 6 weeks hospitalization
Yes/No, % of patients with intended b-BHB (b-BHB ≥ 0,5 mmol/L) in % of intervention days
The occurrence of adverse reactions related to the ketogenic treatment, specified
% of days with adverse effects during intervention
Can patients accept the treatment
Yes/No, % of intervention days
Secondary Outcome Measures
Change in Glasgow Coma Scale (GCS)
Score 3-15, higher score is better outcome
Change in Early Functional Abilities (EFA)
Total score 20-100, higher score is better outcome
Change in Functional Independence Measure (FIM)
Change in Total score 18-126, higher score is better outcome
Change in Functional Oral Intake Scale (FOIS)
Change in Score 1-7, higher score is better outcome
Change in Ranchos Los Amigos Scale (RLAS)
Change in Score 1-8, higher score is better outcome
Full Information
NCT ID
NCT04308577
First Posted
March 6, 2020
Last Updated
July 9, 2021
Sponsor
Jens Rikardt Andersen
Collaborators
Rigshospitalet, Denmark
1. Study Identification
Unique Protocol Identification Number
NCT04308577
Brief Title
Diet Induced Ketosis for Brain Injury - A Feasibility Study
Official Title
Diet Induced Ketosis for Brain Injury - A Feasibility Study: A Ketogenic Diet With MCT Supplementation as a Potential Treatment for Brain Injury in Adults
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
October 5, 2020 (Actual)
Primary Completion Date
February 9, 2021 (Actual)
Study Completion Date
May 31, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jens Rikardt Andersen
Collaborators
Rigshospitalet, Denmark
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Each year, approx. 100 patients with severe brain injury is admitted to the Clinic for Neurorehabilitation/TBI Unit, Rigshospitalet. Severe brain injury results in local oxygen deficiency and acid formation in the brain, which together destroys brain cells. The purpose of this study is to investigate whether it is possible to carry out a ketogenic diet therapy for patients with severe brain injury for six weeks. Ketosis has been shown to be neuroprotective during and after severe brain injury.
Detailed Description
Abstract
At the Department of Highly Specialized Neurorehabilitation/Traumatic Brain Injury, Rigshospitalet (satellite department at Hvidovre Hospital), approximately 100 patients (pt.) are admitted with severe brain damage every year. From 2015 to 2017, 305 pt. were admitted. Out of the 305 pt., 162pt. (53%) had traumatic brain injury (TBI), 48pt. (16%) had apoplexy, 35pt. (12%) had other diagnoses (infections, tumors and almost drowning, etc.), 20pt. (7%) had spontaneous subarachnoid hemorrhage (SAH) and 24pt. (8%) had brain damage as a result of cardiac arrest.
TBI is a leading cause of injury-related morbidity and mortality worldwide. According to the Global Burden of Disease Study (2016), there were 27,08 million new cases of TBI globally in 2016. In Denmark, there were 17.302 new cases of TBI in 2016. Clinical studies have repeatedly shown major changes in cerebral energy metabolism after TBI. The secondary brain injury leads to metabolic cellular dysfunction, cerebral edema, and a complex injury cascade. The injury spread includes processes such as inflammation, edema, free radical damage, oxidative damage, ischemic injury, cerebral glucose metabolism disorder, and ion-mediated cell damage. Much of the neurological dysfunction that occurs in acute TBI also occurs in apoplexy, SAH and cerebral ischemia.
A very important adaptive metabolic response after brain injury is the utilization of alternative cerebral energy substrates, including lactate, but also ketone bodies (KB) such as β-hydroxybutyrate (BHB) and acetoacetate (AcAc). In addition to having a central role in the regulation of cerebral energy metabolism after brain injury, KB has other important neuroprotective properties, including attenuation of oxidative stress, apoptotic cell death, and microglial activation. Increasing KB metabolism through fasting or diet-induced ketosis promotes brain resistance to stress and injury, and attenuates acute cerebral injury. Therefore, supplementing with KB, e.g. through the use of a ketogenic diet (KD) with added medium chain fatty acids (MCT), has emerged as a potential non-pharmacological neuroprotective therapy.
KD has been used for many years for the treatment of refractory epilepsy in children and studies done on adults show promising results, but experience from several studies shows major compliance issues. KD has been shown to reduce cerebral edema and apoptosis, as well as improve cerebral metabolism and behavioral outcomes in TBI rodent models, but clinical human trials on adults with TBI are lacking. Apoplexy animal models show positive effects on pathological and functional outcomes of KD intervention or exogenous ketone administration. The only human trial of KD and apoplexy shows that KD is safe and tolerated by patients with acute apoplexy. Our hypothesis is that diet-induced ketosis will reduce the extent of secondary brain damage. The purpose of the trial is to investigate whether an intervention with a ketogenic diet supplemented with MCT is feasible for 6 weeks on hospitalized pt. with severe brain damage. This is the pre-study for a controlled study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Injuries, Traumatic Brain Injury, Subarachnoid Hemorrhage, Stroke, Anoxic Brain Injury, Neuroinfections
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ketogenic diet with MCT
Arm Type
Experimental
Arm Description
Ketogenic Diet supplemented with MCT everyday for 6 weeks.
Intervention Type
Other
Intervention Name(s)
Ketogenic diet with added MCT
Intervention Description
The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
Primary Outcome Measure Information:
Title
Can the intervention be completed during 6 weeks hospitalization
Description
Yes/No, % of patients with intended b-BHB (b-BHB ≥ 0,5 mmol/L) in % of intervention days
Time Frame
6 weeks
Title
The occurrence of adverse reactions related to the ketogenic treatment, specified
Description
% of days with adverse effects during intervention
Time Frame
6 weeks
Title
Can patients accept the treatment
Description
Yes/No, % of intervention days
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Change in Glasgow Coma Scale (GCS)
Description
Score 3-15, higher score is better outcome
Time Frame
6 weeks
Title
Change in Early Functional Abilities (EFA)
Description
Total score 20-100, higher score is better outcome
Time Frame
6 weeks
Title
Change in Functional Independence Measure (FIM)
Description
Change in Total score 18-126, higher score is better outcome
Time Frame
6 weeks
Title
Change in Functional Oral Intake Scale (FOIS)
Description
Change in Score 1-7, higher score is better outcome
Time Frame
6 weeks
Title
Change in Ranchos Los Amigos Scale (RLAS)
Description
Change in Score 1-8, higher score is better outcome
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with severe acquired brain injury (TBI, stroke, SAH, anoxic brain injury or neuroinfection)
Patients ≥ 18 years
Understand and speak Scandinavian language
Informed consent from patient or deputy consent if the patient is unable to give consent due to reduced state of consciousness
Expectation of prolonged hospitalization
Exclusion Criteria:
Contraindication to a ketogenic diet
Dysregulated Diabetes Mellitus
Medicated for elevated triglycerides
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Edwards, Student
Organizational Affiliation
University of Copenhagen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jens R Andersen, MD,MPA
Organizational Affiliation
University of Copenhagen
Official's Role
Study Director
Facility Information:
Facility Name
Clinic of Neurorehabilitation / TBI Unit, Rigshospitalet (Satellite Department on Hvidovre Hospital)
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Diet Induced Ketosis for Brain Injury - A Feasibility Study
We'll reach out to this number within 24 hrs